Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 235Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 8Xeloda

PharmaCompass

01

Brand Name : Xeloda

Capecitabine

arrow
Fi Europe 2024
Not Confirmed

02

Brand Name : Xeloda

Capecitabine

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Xeloda

arrow
Fi Europe 2024
Not Confirmed

Capecitabine

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 335

2019 Revenue in Millions : 452

Growth (%) : -26

blank

03

Brand Name : Xeloda

Capecitabine

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Xeloda

arrow
Fi Europe 2024
Not Confirmed

Capecitabine

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 209

2020 Revenue in Millions : 319

Growth (%) : -36

blank

04

Brand Name : Xeloda

Capecitabine

arrow
Fi Europe 2024
Not Confirmed

05

Brand Name : Xeloda

Capecitabine

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Xeloda

arrow
Fi Europe 2024
Not Confirmed

Capecitabine

Main Therapeutic Indication : Oncology

Currency : USD

2015 Revenue in Millions : 784

2014 Revenue in Millions : 518

Growth (%) : -34%

blank

06

Brand Name : Xeloda

Capecitabine

arrow
Fi Europe 2024
Not Confirmed

07

Brand Name : Xeloda

Capecitabine

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Xeloda

arrow
Fi Europe 2024
Not Confirmed

Capecitabine

Main Therapeutic Indication : Oncology

Currency : USD

2017 Revenue in Millions : 480

2016 Revenue in Millions : 536

Growth (%) : -10

blank

08

Brand Name : Xeloda

Capecitabine

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Xeloda

arrow
Fi Europe 2024
Not Confirmed

Capecitabine

Main Therapeutic Indication : Oncology

Currency : USD

2018 Revenue in Millions : 431

2017 Revenue in Millions : 458

Growth (%) : -6%

blank